{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:26Z","timestamp":1791521426856,"version":"4.3.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-CD38-based quadruplets such as daratumumab-bortezomib-lenalidomide-dexamethasone (D-VRd) or daratumumab-bortezomib-thalidomide-dexamethasone (D-VTd), where lenalidomide is not reimbursed, are the internationally recommended first-line treatment for transplant-eligible myeloma. There is ongoing debate about whether anti-CD38 exposure impairs stem cell collection. Most studies compare daratumumab-containing with non-daratumumab induction whilst keeping the mobilisation strategy constant. None have compared two mobilisation agents against each other in both daratumumab-exposed and daratumumab-na\u00efve patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed 66 patients (22 received Ara-C, 44 received CY) who were mobilised at a single centre in Poland between 2018 and 2024. No patients received plerixafor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients who were mobilised with Ara-C collected more CD34+ cells than those who received CY, with a median of 12.6 (IQR 9.1\u201315.9) versus 7.7 (4.9\u201312.1) \u00d710\u2076\/kg (p=0.005), with comparable apheresis sessions. Previous D-VTd treatment did not reduce the overall yield (p=0.43). The benefit of Ara-C persisted in the D-VTd subgroup, despite heavy confounding between induction and mobilisation choice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This is the first direct comparison of Ara-C and CY in the daratumumab era. Ara-C-based mobilisation was associated with higher CD34+ yields than CY in a plerixafor-free setting. The apparent advantage in D-VTd-treated patients is exploratory and requires prospective confirmation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1915658","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:13Z","timestamp":1791519973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytarabine-based mobilisation yields higher CD34+ cell counts than cyclophosphamide regardless of prior daratumumab exposure in multiple myeloma"],"prefix":"10.3389","volume":"16","author":[{"given":"Wojciech","family":"Szlasa","sequence":"first","affiliation":[{"name":"Department of Haematology and Cellular Transplantation, Lower Silesian Oncology, Pulmonology and Hematology Center","place":["Wroc\u0142aw, Poland"]},{"name":"Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Borkowski","sequence":"additional","affiliation":[{"name":"Department of Haematology and Cellular Transplantation, Lower Silesian Oncology, Pulmonology and Hematology Center","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Mordak-Domaga\u0142a","sequence":"additional","affiliation":[{"name":"Department of Haematology and Cellular Transplantation, Lower Silesian Oncology, Pulmonology and Hematology Center","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Kwiatkowski","sequence":"additional","affiliation":[{"name":"Department of Haematology and Cellular Transplantation, Lower Silesian Oncology, Pulmonology and Hematology Center","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Malesa","sequence":"additional","affiliation":[{"name":"Department of Haematology and Cellular Transplantation, Lower Silesian Oncology, Pulmonology and Hematology Center","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Sawicki","sequence":"additional","affiliation":[{"name":"Department of Haematology and Cellular Transplantation, Lower Silesian Oncology, Pulmonology and Hematology Center","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Dybko","sequence":"additional","affiliation":[{"name":"Department of Haematology and Cellular Transplantation, Lower Silesian Oncology, Pulmonology and Hematology Center","place":["Wroc\u0142aw, Poland"]},{"name":"Department of Oncology and Hematology, Faculty of Medicine, Wroc\u0142aw University of Science and Technology","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95)","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.09.023","article-title":"Increased efficacy of stem cell chemo-mobilization with intermediate-dose cytarabine plus G-CSF compared with G-CSF alone in patients with multiple myeloma: results of a randomized trial","volume":"25","author":"Czerw","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.269","article-title":"Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid Malignancies, including predicted poor mobilizers","volume":"48","author":"Giebel","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1006.e1","DOI":"10.1016\/j.jtct.2025.08.014","article-title":"The impact of anti-CD38 monoclonal antibody therapy on stem-cell mobilization yields in patients with newly diagnosed multiple myeloma: single center, real world data 2021\u20132024","volume":"31","author":"Uzun","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.04.003","article-title":"Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in patients with newly diagnosed multiple myeloma: a real-world experience at 2 institutes","volume":"25","author":"Varga","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2253479","article-title":"Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation","volume":"64","author":"Eleutherakis-Papaiakovou","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05683-2","article-title":"Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma: a systematic review and meta-analysis","volume":"103","author":"Duan","year":"2024","journal-title":"Ann Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"174.e1","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288411","article-title":"The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study","volume":"111","author":"Valentini","year":"2025","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286332","article-title":"Impact of daratumumab\/bortezomib\/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience","volume":"110","author":"Porrazzo","year":"2025","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21885","article-title":"Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: a multicenter report by the Polish Myeloma Study Group","volume":"36","author":"Drozd-Soko\u0142owska","year":"2021","journal-title":"J Clin Apher"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02233-2","article-title":"Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma","volume":"59","author":"Mohan","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.08.018","article-title":"Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide","volume":"17","author":"Shaughnessy","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102819","article-title":"A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: an Italian explorative cost analysis","volume":"59","author":"Laszlo","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.04.016","article-title":"Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide \u00b1 plerixafor versus granulocyte colony-stimulating factor \u00b1 plerixafor in the lenalidomide era","volume":"27","author":"Johnsrud","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0940-3","article-title":"Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma","volume":"55","author":"Van de Wyngaert","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282269","article-title":"Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study","volume":"108","author":"Dhakal","year":"2023","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01251-8","article-title":"Chemotherapy-based versus chemotherapy-free stem cell mobilization (\u00b1 plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis","volume":"56","author":"Lazzaro","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0396-x","article-title":"Cytarabine plus G-CSF is more effective than cyclophosphamide plus G-CSF as a stem cell mobilization regimen in multiple myeloma","volume":"54","author":"Jelinek","year":"2019","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1915658\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:14Z","timestamp":1791519974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1915658\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1915658"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1915658","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1915658"}}